Favor the Long View on Alnylam (ALNY) Irrespective of Apollo-B Outcome - Oppenheimer Bullish with Outperform Rating, $205 Price Target
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $205.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY) ahead of the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
